Effect of nuclear factor-κB and angiotensin II receptor type 1 on the pathogenesis of rat non-alcoholic fatty liver disease

Role of Innate Immune Response in Non-Alcoholic Fatty Liver Disease: Metabolic Complications and Therapeutic Tools

(2014) Rosaria Meli et al.   Frontiers in Immunology

RanBPM interacts with TβRI, TRAF6 and curbs TGF induced nuclear accumulation of TβRI

(2013) Junwen Zhang et al.   CELLULAR SIGNALLING

Prevalence and associated metabolic factors of fatty liver disease in the elderly

(2013) Zhongli Wang et al.   EXPERIMENTAL GERONTOLOGY

Monascin and ankaflavin act as natural AMPK activators with PPARα agonist activity to down-regulate nonalcoholic steatohepatitis in high-fat diet-fed C57BL/6 mice

(2013) Wei-Hsuan Hsu et al.   FOOD AND CHEMICAL TOXICOLOGY

Resveratrol modulates autophagy and NF-κB activity in a murine model for treating non-alcoholic fatty liver disease

(2013) Lake Li et al.   FOOD AND CHEMICAL TOXICOLOGY

STAT3-mediated attenuation of CCl4-induced mouse liver fibrosis by the protein kinase inhibitor sorafenib

(2013) Yan-Ru Deng et al.   JOURNAL OF AUTOIMMUNITY

Cross talk between toll-like receptor-4 signaling and angiotensin-II in liver fibrosis development in the rat model of non-alcoholic steatohepatitis

(2013) Yusaku Shirai et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

Structural determinants of DISC function: New insights into death receptor-mediated apoptosis signalling

(2013) Tamas Sessler et al.   PHARMACOLOGY & THERAPEUTICS

Experimental nonalcoholic fatty liver disease in mice leads to cytochrome p450 2a5 upregulation through nuclear factor erythroid 2-like 2 translocation

(2013) Yizhe Cui et al.   Redox Biology

Nonalcoholic Fatty Liver Disease

(2012) Angelo H. Paredes et al.   Clinics in Liver Disease

Therapeutic effects of angiotensin II type 1 receptor blocker, irbesartan, on non-alcoholic steatohepatitis using FLS-ob/ob male mice

(2012) Masahiko Koda   INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE

Nonalcoholic fatty liver disease: Current and potential therapies

(2012) Mohamed Abdellah Ibrahim et al.   LIFE SCIENCES

Beneficial effects of candesartan, an angiotensin-blocking agent, on compensated alcoholic liver fibrosis - A randomized open-label controlled study

(2012) Moon Young Kim et al.   LIVER INTERNATIONAL

Viral hepatitis: Human genes that limit infection

(2011) Frank Grünhage et al.   BEST PRACTICE & RESEARCH IN CLINICAL GASTROENTEROLOGY

Aldosterone induction of hepatic stellate cell contraction through activation of RhoA/ROCK-2 signaling pathway

(2011) Hongli Ji et al.   REGULATORY PEPTIDES

Deletion of angiotensin II type I receptor reduces hepatic steatosis

(2009) Yoshitaka Nabeshima et al.   JOURNAL OF HEPATOLOGY

Association between angiotensin II type 1 receptor polymorphisms and the occurrence of nonalcoholic fatty liver disease

(2009) Masato Yoneda et al.   LIVER INTERNATIONAL

Crosstalk via the NF-κB signaling system

(2008) Soumen Basak et al.   CYTOKINE & GROWTH FACTOR REVIEWS

Mitochondrial involvement in non-alcoholic steatohepatitis

(2007) Gaetano Serviddio et al.   MOLECULAR ASPECTS OF MEDICINE

Myofibroblast – like cells and liver fibrogenesis: Emerging concepts in a rapidly moving scenario

(2007) Maurizio Parola et al.   MOLECULAR ASPECTS OF MEDICINE